News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galenea and CHDI Foundation Announce Extension and Expansion of Huntington's Disease Collaboration


8/9/2012 10:32:45 AM

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Galenea Corp. and CHDI Foundation, Inc. announce the extension and expansion of their collaboration to further characterize the synaptic dysfunction apparent in Huntington’s disease (HD) utilizing Galenea’s proprietary synaptic transmission drug discovery platform. Galenea’s innovative platform is providing significant new insights into the disease mechanism, and the collaboration will now focus on extending these findings in order to specifically target this mechanism to discover novel therapies for HD.

Read at BioSpace.com

comments powered by Disqus
Galenea
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES